STORM Therapeutics

STORM Therapeutics is a Cambridge, UK biotechnology company pioneering the field of RNA epigenetics. It designs small-molecule inhibitors of RNA-modifying enzymes to treat cancer and other diseases. Its lead drug, STC-15, is the first RNA-modifying enzyme inhibitor to reach human clinical trials, now in a Phase 2 study for sarcoma.